220 related articles for article (PubMed ID: 2046076)
1. Coronary heart disease risk markers in users of low-dose oral contraceptives.
Godsland IF; Crook D; Wynn V
J Reprod Med; 1991 Mar; 36(3 Suppl):226-37. PubMed ID: 2046076
[TBL] [Abstract][Full Text] [Related]
2. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
3. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
5. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
7. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
9. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
10. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
11. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
12. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS
Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546
[TBL] [Abstract][Full Text] [Related]
14. The metabolic impact of oral contraceptives.
Krauss RM; Burkman RT
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
[TBL] [Abstract][Full Text] [Related]
15. Lipid and biochemical changes after low-dose oral contraception.
Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
[TBL] [Abstract][Full Text] [Related]
16. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles.
Skouby SO; Mølsted-Pedersen L; Kühl C; Bennet P
Fertil Steril; 1986 Nov; 46(5):858-64. PubMed ID: 3781003
[TBL] [Abstract][Full Text] [Related]
18. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
Lachnit-Fixson U
Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
20. Effects of desogestrel on carbohydrate metabolism.
Shoupe D
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
